2016 American Transplant Congress
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
Human cytomegalovirus (CMV) infection is one of the primary opportunistic pathogens and is a leading cause of morbidity and mortality in kidney transplant recipients. Assessing…2016 American Transplant Congress
Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.
Multi-Organ Transplant, University Health Network, Toronto, Canada.
BackgroundSimple standardized measures of global immunity may help predict the risk of infections post-transplant. The Quantiferon-Monitor (QFM) test is a novel interferon-γ (IFN-γ) release assay…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2016 American Transplant Congress
CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients.
Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Cytomegalovirus (CMV) is an important opportunistic infection in kidney transplant recipients (KTR). Whilst pre-emptive or prophylactic anti-viral regime reduce CMV complications, drug toxicity and resistance…2016 American Transplant Congress
Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.
Washington University School of Medicine, Saint Louis, MO.
Background: While CMV prevention strategies have been studied in carefully selected groups of patients enrolled in randomized trials, their comparative effectiveness in real-world settings is…2016 American Transplant Congress
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.
CMV-seronegative kidney transplant recipients (KTRs) from CMV-seropositive donors are at highly increased risk of primary CMV-infection with associated inferior outcomes after kidney transplantation. Presence of…2016 American Transplant Congress
Low Risk of Cytomegalovirus (CMV) Transmission in Clinical Islet Transplantation.
Background:In solid organ transplantation (SOT), CMV is commonly transmitted from seropositive organ donors (D+) to seronegative recipients (R-), despite the use of antiviral prophylaxis. The…2016 American Transplant Congress
Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2016 American Transplant Congress
An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia.
Multi-Organ Transplant, University Health Network, Toronto, ON, Canada.
BackgroundPatients treated for CMV viremia commonly relapse after discontinuation of therapy. CMV-specific CD8+ T-cell mediated immunity (CMI) is useful to predict the risk of CMV…2016 American Transplant Congress
End Stage Renal Disease Patients Have a Skewed T Cell Receptor Vbeta Repertoire.
IntroductionEnd stage renal disease (ESRD) is associated with a defective T-cell mediated immunity, resembling premature T-cell ageing. A diverse T-cell receptor Vbeta (TCR Vβ) repertoire…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 33
- Next Page »